The Meet Our Scientists series presents Ernest Giralt, doctor of chemical sciences, who is the head of the Peptides and Proteins laboratory at IRB Barcelona.
In the video "The power of medicinal chemistry", Giralt highlights his interest in deciphering the language used by proteins to interact with each other.
The Turkish media Aydinlik has published an article about the possibility of using poisons as medicine. The article includes a reference to the research on the use of bee venom as a strategy to selectively eliminate cancer cells, led by Ernest Giralt, leader of the Laboratory of Design, Synthesis and Structure of Peptides and Proteins of IRB Barcelona.
Link to Aydinlik
IRB Barcelona researcher Meritxell Teixidó has participated in the report "Menudes Teràpies" on the programme Quèquicom, broadcasted by Canal 33, There she talked about the advances made by the Design, Synthesis and Structure of Peptides and Proteins Lab, led by Ernest Giralt, regarding drugs with the capacity to overcome the blood-brain barrier and reach the brain.
Link to Menudes Teràpies
Link to additional clip
The technology supplement Innovadores of the newspaper El Mundo has echoed on the award of 220,000 euros to three biomedical innovation projects underway at IRB Barcelona. This funding has been given by the Agency for Management and University and Research Grants (AGAUR, acronym in Catalan) of the Catalan Government, with the support of ERDFs.
The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.
The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.
Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Link to Innovaspain.com
Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.
Link to Agencia SINC
In an interview on the programme “Valencia en la Onda”, presented by Mª Paz Fernández on Radio Onda Cero, Meritxell Teixidó, research associate at IRB Barcelona, talks about his research at the Design, Synthesis and Structure of Peptides and Proteins Laboratory.
During the interview, Teixidó explains the Lab's work on transforming a protein from bee venom into a tool that helps treatments get inside the brain and can be applied to treat central nervous system diseases.
The Nigerian website "24Hours Naija News" devotes a report to the use of insects such as termites and grasshoppers in the treatment of cancer, diabetes, rheumatoid arthritis or Human Immuno-deficiency Virus (HIV).
The article includes a reference to the research on the use of wasp venom as a strategy to kill cancer cells selectively lead by Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona.
Link to 24Hours Naija News
The newspaper “El Mundo” devotes an extensive report to Friedreich's Ataxia through the testimony of Marta, a 13-year-old girl, who began to show the first symptoms of this rare disease when she was only five years old.
The report highlights the research performed by IRB Barcelona aimed to develop an injectable frataxin treatment that can reach the brain. Frataxin is the protein that is reduced in those affected by this disease.
Meritxell Teixidó, the researcher behind the project, which also involves Macarena Sánchez and Ernest Giralt, stresses: "I believe that in 10 or 15years there will be a therapy that turns Friedreich's Ataxia into a chronic disease." And she adds, “...